¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Gene array analysis"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • arterial blood gas analysis
    µ¿¸ÆÇ÷°¡½ººÐ¼®
  • activation analysis
    Ȱ¼ºÈ­ºÐ¼®, ¹æ»çÈ­ºÐ¼®
  • age-period cohort analysis
    ¿¬·É±â°£ÄÚȣƮºÐ¼®
  • analysis
    ºÐ¼®
  • birth cohort analysis
    Ãâ»ýÄÚȣƮºÐ¼®
  • clinical decision analysis
    ÀÓ»óÀÇ»ç°áÁ¤ºÐ¼®
  • clonal analysis
    Ŭ·ÐºÐ¼®
  • cluster analysis
    ¹«¸®ºÐ¼®
  • cohort analysis
    ÄÚȣƮºÐ¼®
  • computer-assisted semen analysis
    ÄÄÇ»ÅÍÁ¤¾×°Ë»ç
  • computerized image analysis
    ÄÄÇ»ÅÍ¿µ»óºÐ¼®
  • control analysis
    ÁöµµºÐ¼®
  • cost-benefit analysis
    ºñ¿ëÆíÀͺм®
  • cost-effectiveness analysis
    ºñ¿ëÈ¿°úºÐ¼®
  • cost-efficiency analysis
    ºñ¿ëÈ¿À²ºÐ¼®
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • suicide gene
    ÀÚ»ìÀ¯ÀüÀÚ
  • supressor gene
    ¾ïÁ¦À¯ÀüÀÚ
  • tumor suppressor gene
    Á¾¾ç¾ïÁ¦À¯ÀüÀÚ
  • gene transfer
    À¯ÀüÀÚÀü´Þ
  • gene translocation
    À¯ÀüÀÚÀüÀ§
  • gene transfection
    1.À¯ÀüÀÚÀü´Þ°¨¿°, 2.À¯ÀüÀÚÇÙ³»ÁÖÀÔ
  • gene therapy
    À¯ÀüÀÚ¿ä¹ý
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • activation analysis
    Ȱ¼ºÈ­ºÐ¼®, ¹æ»çÈ­ºÐ¼®
  • age-period cohort analysis
    ¿¬·É±â°£ÄÚȣƮºÐ¼®
  • antigen analysis
    Ç׿øºÐ¼®
  • birth cohort analysis
    Ãâ»ýÄÚȣƮºÐ¼®
  • case analysis
    Áõ·ÊºÐ¼®
  • clinical decision analysis
    ÀÓ»óÀÇ»ç°áÁ¤ºÐ¼®
  • clonal analysis
    Ŭ·ÐºÐ¼®
  • cluster analysis
    ¹«¸®ºÐ¼®
  • cohort analysis
    ÄÚȣƮºÐ¼®
  • computer-assisted semen analysis
    ÄÄÇ»ÅÍÁ¤¾×°Ë»ç
  • computerized image analysis
    ÄÄÇ»ÅÍ¿µ»óºÐ¼®
  • control analysis
    ÁöµµºÐ¼®
  • cost-benefit analysis
    ºñ¿ëÆíÀͺм®
  • cost-effectiveness analysis
    ºñ¿ëÈ¿°úºÐ¼®
  • cost-efficiency analysis
    ºñ¿ëÈ¿À²ºÐ¼®
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • phased linear array type
    À§»óÂ÷ ¹è¿­½Ä ¼±Çü (êÈßÓó¬ ÛÕÖªãÒ àÊû¡) Æ®·£½ºµà¼­
  • phased-array
    À§»óÂ÷ ¹è¿­ (êÈßÓó¬ ÛÕÖª)
  • DNA sequence analysis
    DNA ¼­¿­ºÐ¼®
  • Data analysis
    Á¤º¸ºÐ¼®
  • Decision analysis
    °áÁ¤ºÐ¼®
  • activation analysis
    Ȱ¼ºÈ­ºÐ¼®(¡­ÝÂà°), ¹æ»çÈ­(Û¯ÞÒûù)ºÐ¼®.
  • activation analysis
    ¹æ»çÈ­ºÐ¼®, Ȱ¼ºÈ­ºÐ¼®
  • amniotic fluid analysis
    ¾ç¼öºÐ¼®
  • analysis
    ºÐ¼®
  • analysis of variance technique
    ºÐ»ê±â¼úºÐ¼®
  • analysis, antigen
    Ç׿øºÐ¼®
  • frequency analysis
    Á֯ļöºÐ¼®
  • gas analysis
    °¡½ººÐ¼®.
  • gas analysis
    °¡½ººÐ¼®
  • gasometric analysis
    ±âüÁ¤·®ºÐ¼®.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • linear sequenced array
    ¼±Çü ¿¬¼â ¹è¿­
  • linear switched array
    ¼±Çü ±³´ë½Ä ¹è¿­
  • mini annular phased array (MAPA)
    ¼Òȯ»ó À§»ó ¹è¿­
  • phased array
    À§»óÂ÷ ¹è¿­
  • phased array
    À§»ó ¹è¿­
  • phased array coil
    À§»ó Á¤·Ä ÄÚÀÏ
  • phased array scanner
    À§»ó ¹è¿­ ½ºÄ³³Ê
  • phased linear array type
    À§»óÂ÷ ¹è¿­½Ä ¼±Çü (êÈßÓó¬ ÛÕÖªãÒ àÊû¡) Æ®·£½ºµà¼­
  • phased linear array type
    À§»óÂ÷ ¼±Çü ¹è¿­½Ä
  • phased-array
    À§»óÂ÷ ¹è¿­ (êÈßÓó¬ ÛÕÖª)
  • steered array
    Á¶Çâ½Ä ¹è¿­
  • switched array
    ±³´ë½Ä ¹è¿­
  • activation analysis
    ¹æ»çÈ­ºÐ¼®, Ȱ¼ºÈ­ºÐ¼®
  • activation analysis
    Ȱ¼ºÈ­ºÐ¼®(¡­ÝÂà°), ¹æ»çÈ­(Û¯ÞÒûù)ºÐ¼®.
  • amniotic fluid analysis
    ¾ç¼öºÐ¼®
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • ionic mobility analysis
    À̿ À̵¿µµ(ì¹ÔÑÓø) ºÐ¼®(ÝÂà°)
  • isoelectric analysis
    µîÀüºÐ¼®(Ôõï³ÝÂà°)
  • isotope dilution analysis
    µ¿À§¿ø¼Ò Èñ¼®ºÐ¼®(ÔÒêÈêªáÈýüà·ÝÂà°)
  • isotopic dilution analysis
    µ¿À§¿ø¼Ò Èñ¼®ºÐ¼®(ÔÒêÈêªáÈýüà·ÝÂà°)
  • kinetic analysis
    ¹ÝÀÀ¼ÓµµºÐ¼®(ÚãëëáÜÓøÝÂà°)
  • methylation analysis
    ¸Þƿȭ(ûù)ºÐ¼®(ÝÂà°)
  • mobility shift analysis
    À̵¿µµ(ì¹ÔÑÓø)¿Å±è ºÐ¼®(ÝÂà°)
  • moving boundary analysis
    À̵¿°æ°è ºÐ¼®(ì¹ÔÑÌÑÍ£ÝÂà°)
  • multiple inhibition analysis
    ´ÙÁß(Òýñì)ÀúÇØ ºÐ¼®(îÁúªÝÂà°)
  • nearest-neighbor base frequency analysis
    ÃÖ±ÙÁ¢ ¿°±â ºóµµºÐ¼®(õÌÐÎïÈç¤ÐñÞºÓøÝÂà°)
  • proximate analysis
    ±Ù»çºÐ¼®(ÐÎÞÄÝÂà°)
  • radioactive analysis
    ¹æ»ç¼º ºÐ¼®(Û¯ÞÒàõÝÂà°)
  • radiometric analysis
    ¹æ»ç¹ý ºÐ¼® (Û¯ÞÒÛöÝÂà°)
  • saturation analysis
    Æ÷È­ ºÐ¼®(øéûùÝÂà°)
  • volumetric analysis
    ºÎÇÇ ºÐ¼®(ÝÂà°)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • annular array
    À±»ó¹è¿­, ȯÇü¹è¿­
  • array
    ¹è¿­, ¾î·¹ÀÌ
  • array system
    ¹è¿­ÀåÄ¡, ¹è¿­Ã¼°è
  • coil array
    ÄÚÀϹ迭
  • disk array
    µð½ºÅ©¾î·¹ÀÌ
  • electronic array scanner
    ÀüÀڹ迭½ºÄ³³Ê
  • linear array
    ¼±Çü ¹è¿­
  • linear phased array
    ¼±ÇüÀ§»óÂ÷¹è¿­
  • linear sequenced array
    ¼±Çü¿¬¼â¹è¿­
  • linear switched array
    ¼±Çü±³´ë½Ä¹è¿­
  • linear transducer array
    ¼±»óÆ®·£½ºµà¼­¹è¿­
  • mini annular phased array (MAPA)
    ¼Òȯ»óÀ§»ó¹è¿­
  • phased array
    À§»ó¹è¿­
  • phased array coil
    À§»ó¹è¿­ÄÚÀÏ, À§»óÁ¤·ÄÄÚÀÏ
  • phased array scanner
    À§»ó¹è¿­½ºÄ³³Ê
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
MEDPAR Medical Provider Analysis and Review; Medicare Provider Analysis and Review
MRA magnetic resonance angiography; main renal artery; marrow repopulation activity; medical record anal...
CGRP Calcitonin Gene Related Peptide(Protein)
CGRPs Calcitonin Gene-Related Products
GnRH Gonadotropin Releasing Hormone  [HP 1898, 2034]
  = LHRH
  = Go...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
MANOVA 2-multivariate analysis of variance
ANOVA ANalysis Of VAriance
ARDRA Amplified ribosomal DNA restriction analysis
BIA Bio-electrical impedance analysis
BIA Bioelectric Impedance Analysis
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • histocompatibility gene
    Á¶Á÷ ÀûÇÕ À¯ÀüÀÚ, Á¶Á÷ ÀûÇÕ¼º À¯ÀüÀÚ
    ÀÌ½ÄµÈ Á¶Á÷À» ÀÚ±â Á¶Á÷ ¶Ç´Â ¿ÜºÎ Á¶Á÷À¸·Î ÀνÄÇÏ´Â À¯ÀüÀÚ.
  • Is gene
    Is À¯ÀüÀÚ
  • marker gene
    Ç¥Áö À¯ÀüÀÚ
  • multiple drug resistance gene
    º¹ÇÕ ¾àÁ¦ ³»¼º À¯ÀüÀÚ
  • mutable gene
    À̺¯ À¯ÀüÀÚ
  • mutator gene
    º¯ÀÌ À¯¹ß À¯ÀüÀÚ
  • nucleolar gene
    ÇÙ ¼Òü À¯ÀüÀÚ
  • operator gene
    ÀÛµ¿ À¯ÀüÀÚ
  • recessive gene
    ¿­¼º À¯ÀüÀÚ
    ¿­¼º ÈÄÅð ¶Ç´Â ÇÔ¿äÇϱ⠽¬¿î °Í. Áö¹è·ÂÀ» ³ªÅ¸³»Áö ¸øÇϰųª ¿µÇâ·ÂÀ» ÅëÁ¦ÇÏÁö ¸øÇÏ´Â °Í. À¯ÀüÇп¡¼­´Â ´ë¸³ À¯ÀüÀÚ°¡ »óµ¿ ¿°»öü »ó¿¡ ¾øÀ¸¸é ÇüÁúÀ» ¹ßÇöÇÏÁö ¸øÇÏ´Â °Í.
  • regulator gene
    Á¶Àý À¯ÀüÀÚ
  • regulatory gene
    Á¶Àý À¯ÀüÀÚ
  • structural gene
    ±¸Á¶ À¯ÀüÀÚ
  • virulence gene
    µ¶¼º À¯ÀüÀÚ
  • analysis
    ºÐ¼®
    ¼ººÐ°ú ¿ä¼Ò·Î ºÐÇØÇÏ´Â °Í. ¹°ÁúÀÇ ¼ººÐÀ» °áÁ¤ÇÏ´Â ÇàÀ§.
  • atomic absorption analysis
    ¿øÀÚ Èí±¤ ºÐ¼®
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
pedigree analysis The formal study of the pattern of a trait in a pedigree to determine such properties as its mode of inheritance, age of onset, and variability in phenotype.
(05 Mar 2000)
volumetric analysis Quantitative analysis by the addition of graduated amounts of a standard test solution to a solution of a known amount of the substance analyzed, until the reaction is just at an end; depends upon the stoichiometric nature of the reaction between the test solution and the unknown.
(05 Mar 2000)
cephalometric analysis A study of the skeletal and dental relationships used in orthodontic case analysis.
(05 Mar 2000)
percept analysis Psychologic survey of an individual's personality using Rorschach's series of inkblots.
(05 Mar 2000)
character analysis Analysis of the defenses and personality traits that characterise an individual.
(05 Mar 2000)
meta-analysis <statistics> A quantitative method of combining the results of independent studies (usually drawn from the published literature) and synthesizing summaries and conclusions which may be used to evaluate therapeutic effectiveness or to plan new studies.
With application chiefly in the areas of research and medicine. It is often an overview of clinical trials. It is usually called a meta-analysis by the author or sponsoring body and should be differentiated from reviews of the literature.
(27 Jun 1999)
cluster analysis A set of statistical methods used to group variables or observations into strongly inter-related subgroups. In epidemiology, it may be used to analyze a closely grouped series of events or cases of disease or other health-related phenomenon with well-defined distribution patterns in relation to time or place or both.
(12 Dec 1998)
Western blot analysis A procedure in which proteins separated by electrophoresis in polyacrylamide gels are transferred (blotted) onto nitrocellulose or nylon membranes and identified by specific complexing with antibodies that are either pre-or post-tagged with a labelled secondary protein.
See: immunoblot.
Synonym: Western blot, Western blotting.
Origin: coined to distinguish it from eponymic Southern blot a.
(05 Mar 2000)
combustion analysis <technique> A method for determining the chemical composition of a compound by burning the compound under controlled conditions. Often used to determine the relative amounts of carbon and hydrogen in a compound.
(09 Oct 1997)
multivariate analysis A set of techniques used when variation in several variables has to be studied simultaneously. In statistics, multivariate analysis is interpreted as any analytic method that allows simultaneous study of two or more dependent variables.
(12 Dec 1998)
content analysis Any of a variety of techniques for classification and study of the verbal products of normal or of psychologically disabled individuals.
(05 Mar 2000)
cost-benefit analysis A method of comparing the cost of a program with its expected benefits in dollars (or other currency). The benefit-to-cost ratio is a measure of total return expected per unit of money spent. This analysis generally excludes consideration of factors that are not measured ultimately in economic terms. Cost effectiveness compares alternative ways to achieve a specific set of results.
(12 Dec 1998)
costs and cost analysis Absolute, comparative, or differential costs pertaining to services, institutions, resources, etc., or the analysis and study of these costs.
(12 Dec 1998)
half-tetrad analysis <genetics> The analysis of tetrad chromosomes (a pair of homologous chromosomes, thus four total chromosomes) after recombination when only half of the tetrad (two of the four chromosomes) can be analysed.
(13 Nov 1997)
predisposition analysis <genetics> The analysis of how some people are more likely to get certain diseases as a result of their genetic make-up.
(31 Dec 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • gene therapy
    À¯ÀüÀÚ ¿ä¹ý(°á¼ÕµÈ À¯ÀüÀÚ¸¦ º¸ÃæÇÏ¿© À¯Àüº´À» °íÄ¡´Â ¿ä¹ý)
  • nif gene
    (»ýÈ­)Áú¼Ò °íÁ¤¿¡ °ü¿©ÇÏ´Â À¯ÀüÀÚ
  • recessive gene
    ¿­¼º À¯ÀüÀÚ
  • regulator(regulatory) gene
    Á¶Àý(Á¦¾î)À¯ÀüÀÚ
  • restorer gene
    ȸº¹ À¯ÀüÀÚ
  • analysis
    ºÐÇØ
  • analysis
    ºÐ¼®;ÇØ¼®;ºÐÇØ
  • conformational analysis
    ¹èÁÂ ÇØ¼®
  • content analysis
    ³»¿ë ºÐ¼®
  • critical path analysis (method)
    Å©¸®Æ¼Äà ÆÐ½º ºÐ¼®¹ý(ÇÁ·ÎÁ§Æ®ÀÇ °èȹ.°ü¸®¸¦ °úÇÐÀûÀ¸·Î ÇÏ´Â ¹æ¹ý)
  • dream analysis
    ²Þ ºÐ¼®
  • factor analysis
    ÀÎÀÚ ºÐ¼®
  • harmonic analysis
    Á¶È­ ºÐ¼®;Á¶È­ ÇØ¼®;Á¶ÆÄ ºÐ¼®
  • high analysis
    (ºñ·á°¡)½Ä¹°ÀÇ ÇÊ¿ä ¾çºÐÀÇ 20% ÀÌ»óÀ» ÇÔÀ¯ÇÏ´Â
  • inputoutput analysis
    ÅõÀÔ»êÃâºÐ¼®
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á